Literature DB >> 3052053

Hydroxychloroquine treatment of rheumatoid arthritis.

R I Rynes1.   

Abstract

A variety of placebo-controlled and open studies have demonstrated the effectiveness of hydroxychloroquine in the treatment of rheumatoid arthritis. The excellent responses to recurrent treatment in a sample patient illustrate the value of hydroxychloroquine. Because low daily doses of hydroxychloroquine are associated with greater ophthalmologic safety, it would be advantageous to use the smallest effective daily dose, but there are no published controlled efficacy studies using daily doses of less than 400 mg. Hydroxychloroquine may best be employed to treat patients with new onset of disease or those in whom disease is not rapidly progressive. Great potential exists for the use of hydroxychloroquine in combination therapy, but optimal utilization of combination regimens will require performances of additional controlled studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052053     DOI: 10.1016/0002-9343(88)90357-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.

Authors:  Entela Nuri; Mara Taraborelli; Laura Andreoli; Marta Tonello; Maria Gerosa; Antonia Calligaro; Lorenza Maria Argolini; Rajesh Kumar; Vittorio Pengo; Pier Luigi Meroni; Amelia Ruffatti; Angela Tincani
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity.

Authors:  S Pasadhika; G A Fishman; D Choi; M Shahidi
Journal:  Eye (Lond)       Date:  2010-04-16       Impact factor: 3.775

3.  Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  E F Morand; P I McCloud; G O Littlejohn
Journal:  Ann Rheum Dis       Date:  1992-12       Impact factor: 19.103

4.  Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers.

Authors:  Y A de Reus; P Hagedoorn; M G G Sturkenboom; F Grasmeijer; M S Bolhuis; I Sibum; H A M Kerstjens; H W Frijlink; O W Akkerman
Journal:  PLoS One       Date:  2022-08-05       Impact factor: 3.752

5.  Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study.

Authors:  Soumita Mukherjee; Subrata Dasgupta; Tapasendra Adhikary; Utpal Adhikari; Sujit Sankar Panja
Journal:  J Biomol Struct Dyn       Date:  2020-08-10

6.  Does hydroxychloroquine still have any role in the COVID-19 pandemic?

Authors:  William Hk Schilling; Nicholas J White
Journal:  Expert Opin Pharmacother       Date:  2021-03-16       Impact factor: 3.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.